Polymer Delivery Systems for Long-Acting Antiretroviral Drugs.
Mohammad Ullah NayanSudipta PanjaAshrafi SultanaLubaba A ZamanLalitkumar K VoraBrady SillmanHoward E GendelmanBenson EdagwaPublished in: Pharmaceutics (2024)
The success of long-acting (LA) drug delivery systems (DDSs) is linked to their biocompatible polymers. These are used for extended therapeutic release. For treatment or prevention of human immune deficiency virus type one (HIV-1) infection, LA DDSs hold promise for improved regimen adherence and reduced toxicities. Current examples include Cabenuva, Apretude, and Sunlenca. Each is safe and effective. Alternative promising DDSs include implants, prodrugs, vaginal rings, and microarray patches. Each can further meet patients' needs. We posit that the physicochemical properties of the formulation chemical design can optimize drug release profiles. We posit that the strategic design of LA DDS polymers will further improve controlled drug release to simplify dosing schedules and improve regimen adherence.
Keyphrases
- drug release
- drug delivery
- end stage renal disease
- newly diagnosed
- endothelial cells
- ejection fraction
- chronic kidney disease
- hiv infected
- prognostic factors
- antiretroviral therapy
- hiv positive
- peritoneal dialysis
- type diabetes
- metabolic syndrome
- hiv aids
- hiv infected patients
- glycemic control
- replacement therapy
- insulin resistance
- pluripotent stem cells
- hepatitis c virus
- men who have sex with men
- smoking cessation
- drug induced
- patient reported